FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION
GHK-CUGIGARESEARCH

GHK-CU · SUBTOPIC · SAFETY PROFILE

GHK-Cu Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of GHK-Cu.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of GHK-Cu. Severity, frequency, and attribution depend on the source publication.

  • Localized erythema (injection site)
  • Transient hyperpigmentation (topical, in some users)
  • Rare contact dermatitis

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for GHK-Cu.

  • Vitamin C (theoretical · copper-ascorbate redox cycling)
  • Retinoids (may potentiate irritation when stacked topically)

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for GHK-Cu in the published record:

  • Wilson's disease (copper-accumulation disorder)
  • Active malignancy at the local site (theoretical, due to angiogenic activity)

FDA REGULATORY STATUS

Topical GHK-Cu formulations are marketed as cosmetic ingredients under FDA cosmetic regulation (cosmetics generally do not require FDA premarket approval). Injectable forms are research-use only.

WADA REGULATORY STATUS

Not listed on the WADA Prohibited List (2026).

SAFETY Q+A FROM LITERATURE

Is GHK-Cu FDA-approved?

Topical GHK-Cu is regulated as a cosmetic ingredient (no FDA premarket approval required for cosmetics). Injectable formulations are not FDA-approved for any human indication and are supplied as research-grade chemical reference compounds.

Is GHK-Cu banned by WADA?

GHK-Cu is not currently on the WADA Prohibited List as of the 2026 publication.

Is GHK-Cu safe in pregnancy?

Not studied in pregnancy or lactation. Research-grade GHK-Cu is supplied for in-vitro use only; no human dose is recommended.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

  • Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008. PMID 18644225. link
  • Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Oxid Med Cell Longev 2012. PMID 22666519. link
  • Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018. PMID 29986520. link
  • Canapp SO Jr, et al.. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg 2003. PMID 14648531. link

RELATED PAGES

GHK-CU OVERVIEWMECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-19

© 2026 GigaCompounds LLC · For Laboratory Research Use Only